NEW YORK, July 10 (Reuters) - Insmed Inc said on Thursday its version of Amgen Inc's drug Neupogen, for boosting white blood cells, showed equivalence in a small study, moving Insmed closer to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback